Gene & Cell Therapy vs FDA Actions

Side-by-side coverage analysis for Gene & Cell Therapy and FDA Actions.

Gene & Cell Therapy

CRISPR, CAR-T, gene editing

Stories
8
Avg Impact
6.9/10
Dominant Tone
Neutral
Latest
Mar 19, 2026

Sentiment breakdown

View all Gene & Cell Therapy stories →

FDA Actions

Approvals, rejections, priority reviews

Stories
0
Avg Impact
0/10
Dominant Tone
Very Bullish

Sentiment breakdown

View all FDA Actions stories →

Recent Headlines

Gene & Cell Therapy

  1. Neutral ●●○
    Rocket Pharmaceuticals Shares Slide 4.4% Amid Regulatory and Financing Shifts
  2. Neutral ●●○
    REGENXBIO Q4 Earnings Miss Highlights Gene Therapy Sector Volatility
  3. Neutral ●●○
    Colossal Biosciences Faces Ethical Scrutiny Over Mammoth De-Extinction Goals
  4. Neutral ●●○
    uniQure Eyes 2029 Runway as FDA Talks for Huntington's Gene Therapy Continue
  5. Very Bullish ●●●
    B.C. Man Cured of Rare Disease in Landmark CRISPR Gene-Editing Success
  6. Very Bullish ●●●
    B.C. Teen Becomes First in World Cured of Rare Disease via Gene Editing
  7. Neutral ●●○
    Gene Therapy Access Gap: High Costs and Logistics Stifle Medical Revolution
  8. Bullish ●●●
    FDA Accelerates Gene Therapy Approvals via 'Plausible Mechanism' Framework

FDA Actions

No recent stories found.